TY - JOUR
T1 - Factors associated with the development of neonatal hypoglycemia after antenatal corticosteroid administration
T2 - It's all about timing
AU - Zigron, Roy
AU - Rotem, Reut
AU - Erlichman, Ira
AU - Rottenstreich, Misgav
AU - Rosenbloom, Joshua I.
AU - Porat, Shay
AU - Rottenstreich, Amihai
N1 - Publisher Copyright: © 2021 International Federation of Gynecology and Obstetrics.
PY - 2022/8
Y1 - 2022/8
N2 - Objective: To determine the factors associated with neonatal hypoglycemia among neonates exposed to antenatal corticosteroid (ACS). Methods: A retrospective study conducted during 2017–2019 at a tertiary-care center including all neonates delivered between 24 and 34 weeks of gestation after ACS administration. The primary outcome was neonatal hypoglycemia (<40 mg/dl). Results: Overall, 362 early preterm neonates, including 205 singletons and 157 twins, were exposed to ACS before delivery and constituted the study group. Of them, 275 (76.0%) were exposed to a single ACS course and 87 (24.0%) to an additional rescue ACS course. Neonatal hypoglycemia occurred in 84 (23.2%) neonates. The incidence of neonatal hypoglycemia was significantly higher in those delivered between 24 and 48 h after ACS administration compared with those delivered outside this time interval (10/25, 40.0% vs 74/337, 21.9%; P = 0.049). In multivariate analysis, after adjusting for neonatal birth weight and gestational age, delivery within 24–48 h after ACS administration was the only independent risk factor associated with neonatal hypoglycemia (adjusted odds ratio 2.41, 95% confidence interval 1.03–5.68; P = 0.044). Conclusion: Neonatal hypoglycemia occurred in over one-fifth of those exposed to ACS, and was independently associated with delivery between 24 and 48 h after ACS administration.
AB - Objective: To determine the factors associated with neonatal hypoglycemia among neonates exposed to antenatal corticosteroid (ACS). Methods: A retrospective study conducted during 2017–2019 at a tertiary-care center including all neonates delivered between 24 and 34 weeks of gestation after ACS administration. The primary outcome was neonatal hypoglycemia (<40 mg/dl). Results: Overall, 362 early preterm neonates, including 205 singletons and 157 twins, were exposed to ACS before delivery and constituted the study group. Of them, 275 (76.0%) were exposed to a single ACS course and 87 (24.0%) to an additional rescue ACS course. Neonatal hypoglycemia occurred in 84 (23.2%) neonates. The incidence of neonatal hypoglycemia was significantly higher in those delivered between 24 and 48 h after ACS administration compared with those delivered outside this time interval (10/25, 40.0% vs 74/337, 21.9%; P = 0.049). In multivariate analysis, after adjusting for neonatal birth weight and gestational age, delivery within 24–48 h after ACS administration was the only independent risk factor associated with neonatal hypoglycemia (adjusted odds ratio 2.41, 95% confidence interval 1.03–5.68; P = 0.044). Conclusion: Neonatal hypoglycemia occurred in over one-fifth of those exposed to ACS, and was independently associated with delivery between 24 and 48 h after ACS administration.
KW - antenatal corticosteroid
KW - betamethasone
KW - delivery timing
KW - hypoglycemia
KW - outcomes
KW - preterm delivery
UR - http://www.scopus.com/inward/record.url?scp=85118356978&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/ijgo.13975
DO - https://doi.org/10.1002/ijgo.13975
M3 - مقالة
C2 - 34625970
SN - 0020-7292
VL - 158
SP - 385
EP - 389
JO - International Journal of Gynecology and Obstetrics
JF - International Journal of Gynecology and Obstetrics
IS - 2
ER -